The long-term therapy of MG with ACh inhibitors leads to significant adverse effects, [104], and notably only AChR MG patients properly respond, whereas other autoantibodies mediated MG such as MuSK MG patients don’t respond. This evidence concerns the gene MUSK and myasthenia gravis.